secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211921
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven reports Q1 net loss of $23.6M; cash $452.4M; ELVN-001 Phase 1 data mid-2026
--------------------------------------------------------------------------------

- Net loss of $23.6M in Q1 2026 vs. $28.5M in Q1 2025; R&D spend $20.7M.
- Cash, cash equivalents and marketable securities of $452.4M as of March 31, 2026; runway into first half of 2029.
- Phase 1 data update for ELVN-001 expected mid-2026; Phase 3 ENABLE-2 initiation expected H2 2026.
- ELVN-001 is a potentially best-in-class ATP-competitive BCR::ABL inhibitor for CML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526211921/0001193125-26-211921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526211921/elvn-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer